Vogenx Inc Common Stock (VOGX) stock: key figures, P/E, revenue and dividend
Health Care · United States
Vogenx Inc Common Stock financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 USD | 0.00 USD |
| Operating income | -2.30 m USD | -1.44 m USD |
| EBIT | -2.30 m USD | -1.44 m USD |
| Net income | -2.20 m USD | -1.45 m USD |
| Diluted EPS – continuing operations | -0.16 USD | -0.10 USD |
Full history since 2024, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
More stocks
- Hangzhou SDIC Microelectronics Inc. A (688130.SS)
- Bangyan Technology Co. Ltd. A (688132.SS)
- Everyday Network (300295.SZ)
- Beijing Jiaoda Signal Technology (300851.SZ)
- Ever Ohms Technology Co. Ltd. (6834.TW)
- Real Consulting IT Business Solutions S.A. (REALCONS.AT)
- Good Will Instrument Co Ltd (2423.TW)
- Heungkuk Fire & Marine Insurance Co Ltd (000545.KS)
- Tivan Ltd (TVN.AX)
- Shanghai Huaming Intelligent Terminal Equipment Co Ltd (300462.SZ)
- Doosan Fuel Cell Co. Ltd. Pfd. Series 1 (33626K.KS)
- Jiangsu Huaxin New Material Co Ltd Class A (300717.SZ)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.